City of Hope researchers found kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug, Fotivda (tivozanib), compared to an alternative approved by FDA.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe